Dulaglutide vs Semaglutide
How they differ
- FDA status, the same for both (FDA-approved). Dulaglutide: FDA-approved as Trulicity.1,2 Semaglutide: FDA-approved as Ozempic, Rybelsus and Wegovy.3,4,5,6
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Dulaglutide | Semaglutide |
|---|---|---|
| What it is | A GLP-1 receptor agonist. The label states that dulaglutide has 90% amino acid sequence similarity to human GLP-1.1 | A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.3 |
| FDA status | FDA-approved FDA-approved. Drugs@FDA lists Trulicity with an original approval date of September 18, 2014. The label carries a boxed warning about thyroid C-cell tumors in rats.1,2 | FDA-approved FDA-approved as Ozempic, Rybelsus and Wegovy3,4,5,6 FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.3,4,5,6 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.7 | Not among the six peptides the policy lists.7 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 11 ClinicalTrials.gov records and 38 PubMed records collected | 140 ClinicalTrials.gov records and 108 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 2Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 4Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 7HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 9FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026